Aptorum Group Limited: Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1

Related Keywords

Singapore ,Dennis Riedl ,Clark Cheng ,Craig Brelsford ,Ghislaine Gasparetto ,Aptorum Group Form ,Aptorum Group Or ,Drug Administration ,Singapore Agency For Science ,Actifin Financial Communications Europe ,Redchip Financial Communications United States ,Daptorum Group ,Aptorum Group Limited Nasdaq ,Regulatory News ,Group Limited ,Euronext Paris ,Chief Medical Officer ,Executive Director ,Aptorum Group Limited ,Securities Litigation Reform Act ,French Autorit ,Des March ,Regulations Delegated ,Financial Communications United States ,Financial Communications Europe ,Aptorum ,Group ,Imited ,Nnounces ,Completion ,Hase ,Top1 ,Meeting ,Fact ,Repurposed ,Mall ,Olecule ,Drug ,Targeting ,Neuroblastoma ,